Loading...
XNAS
ELUT
Market cap11mUSD
Dec 05, Last price  
0.69USD
1D
0.20%
1Q
-63.10%
IPO
-51.26%
Name

Aziyo Biologics Inc

Chart & Performance

D1W1MN
XNAS:ELUT chart
P/E
P/S
0.46
EPS
Div Yield, %
Shrs. gr., 5y
22.20%
Rev. gr., 5y
-10.69%
Revenues
24m
-1.50%
39,038,00042,901,00042,682,00047,390,00023,849,00024,745,00024,375,000
Net income
-54m
L+43.27%
-11,566,000-11,939,000-21,825,000-24,832,000-32,897,000-37,656,000-53,949,000
CFO
-23m
L+4.12%
-5,125,000-8,446,000-13,435,000-15,618,000-21,902,000-21,761,000-22,657,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Aziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. It offers CanGaroo that combines the envelope with antibiotics and is designed to reduce the risk of infection following surgical implantation of an electronic device. The company also provides cardiovascular products, such as ProxiCor for use as an intracardiac patch or pledget for tissue repairs; Tyke for use in neonates and infants to repair pericardial structures; and VasCure, a patch material to repair or reconstruct the peripheral vasculature, including the carotid, renal, iliac, femoral, and tibial blood vessels for cardiovascular, vascular, and general surgeons. In addition, it offers Fiber VBM, ViBone, and OsteGro V that are human tissue-derived bone allografts designed to protect and preserve native bone cells; and SimpliDerm, a pre-hydrated HADM designed to repair or replacement of damaged or inadequate integumental tissues. Further, the company provides contract manufacturing services for various products to corporate customers. It sells its products to hospitals and other healthcare facilities through its direct sales force, commercial partners, and independent sales agents. The company was incorporated in 2015 and is headquartered in Silver Spring, Maryland.
IPO date
Oct 08, 2020
Employees
151
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT